Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.305
Sell
RSI(14)
36.468
Neutral
STOCH(KDJ)(9,3,3)
27.065
Neutral
ATR(14)
0.648
Low Volatility
CCI(14)
-63.948
Neutral
Williams %R
79.221
Sell
TRIX(12,20)
-0.397
Sell
StochRSI(14)
79.089
Neutral
Smith & Nephew PLC
SNN32.270USD
-0.180-0.55%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
14.11BMarket Cap
28.71P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Smith & Nephew PLC
Currency: USD Updated: 2026-03-25Key Insights
Smith & Nephew PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 81 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 36.28.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Smith & Nephew PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Smith & Nephew PLC Highlights
StrengthsRisks
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.16B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.
Undervalued
The company’s latest PE is 28.87, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.27M shares, decreasing 24.13% quarter-over-quarter.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 603.81K shares of this stock.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
36.278
Target Price
+13.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-25The current financial score of Smith & Nephew PLC is 8.87, ranking 15 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high.
Score
Financials
6.36
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
8.01
Smith & Nephew PLC's Company Valuation
Currency: USD Updated: 2026-03-25The current valuation score of Smith & Nephew PLC is 3.98, ranking 197 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 28.87, which is 56.57% below the recent high of 45.21 and 9.61% above the recent low of 26.10.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 81/209
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-25The current earnings forecast score of Smith & Nephew PLC is 6.80, ranking 160 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 35.75, with a high of 39.00 and a low of 26.13.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
36.278
Target Price
+12.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
115
Total
6
Median
9
Average
Company name
Ratings
Analysts
Smith & Nephew PLC
SNN
5
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-25The current price momentum score of Smith & Nephew PLC is 6.72, ranking 101 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 35.76 and the support level at 30.46, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
32.152
Buy
MA10
32.545
Sell
MA20
33.697
Sell
MA50
34.261
Sell
MA100
33.774
Sell
MA200
33.974
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-25The current institutional shareholding score of Smith & Nephew PLC is 3.00, ranking 135 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 7.59%, representing a quarter-over-quarter decrease of 1.61%. The largest institutional shareholder is Brandes Investmen, holding a total of 1.18M shares, representing 0.28% of shares outstanding, with 20.98% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
River Road Asset Management, LLC
BMO Capital Markets (US)
Scharf Investments, LLC
BofA Global Research (US)
Goldman Sachs Asset Management, L.P.
Parametric Portfolio Associates LLC
Todd Asset Management LLC
BNP Paribas Securities Corp. North America
Dimensional Fund Advisors, L.P.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-25The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Smith & Nephew PLC is 8.13, ranking 27 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.71
VaR
+2.56%
240-Day Maximum Drawdown
+17.57%
240-Day Volatility
+31.02%
Return
Best Daily Return
60 days
+3.20%
120 days
+3.20%
5 years
+15.23%
Worst Daily Return
60 days
-5.29%
120 days
-11.72%
5 years
-13.03%
Sharpe Ratio
60 days
-0.08
120 days
-0.70
5 years
-0.01
Risk Assessment
Maximum Drawdown
240 days
+17.57%
3 years
+33.69%
5 years
+51.21%
Return-to-Drawdown Ratio
240 days
+1.45
3 years
+0.02
5 years
-0.10
Skewness
240 days
+1.12
3 years
+0.02
5 years
-0.04
Volatility
Realised Volatility
240 days
+31.02%
5 years
+28.02%
Standardised True Range
240 days
+1.87%
5 years
+1.77%
Downside Risk-Adjusted Return
120 days
-71.88%
240 days
-71.88%
Maximum Daily Upside Volatility
60 days
+24.51%
Maximum Daily Downside Volatility
60 days
+23.67%
Liquidity
Average Turnover Rate
60 days
+0.11%
120 days
+0.10%
5 years
--
Turnover Deviation
20 days
-2.29%
60 days
+3.50%
120 days
-3.35%
Peer Comparison
Healthcare Equipment & Supplies
Smith & Nephew PLC
SNN
6.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
WST
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.10 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
